human | Q5 |
P496 | ORCID iD | 0000-0002-6443-5500 |
P1053 | ResearcherID | D-7967-2016 |
P735 | given name | Barbara | Q153957 |
Barbara | Q153957 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | female | Q6581072 |
Q41318201 | Antigenicity, immunogenicity and passive protection induced by immunization of mice with baculovirus-expressed VP7 protein from rhesus rotavirus |
Q38915583 | CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses. |
Q71709184 | Comparison of capillary blood versus venous blood samples in the assessment of immunity to measles |
Q73416485 | Cross-reactivity between the major Parietaria allergen and rotavirus VP4 protein |
Q34978901 | HIV-1 Tat-based vaccines: from basic science to clinical trials |
Q34477471 | HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies |
Q35232797 | HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response |
Q36498248 | IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer |
Q39398034 | Infection of a simian B cell line by human and simian immunodeficiency viruses |
Q51998598 | Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. |
Q73594074 | Measles vaccine in egg allergic children: poor immunogenicity of the Edmoston-Zagreb strain |
Q24674143 | Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors |
Q35700273 | On the role of interferon regulatory factors in HIV-1 replication. |
Q74465301 | Seroepidemiological evaluation of 1989-91 mass vaccination campaigns against measles, in Italy |
Q56897975 | Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability |
Q37539231 | The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant. |
Q33769629 | The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines |
Search more.